← Leaderboards
Emil Khisamutdinov
Ball State University
$1,167,272
Attributed
$1,167,272
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $560.5K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,167,272 · 2
By mechanism
R15$1,017,571 · 1
R03$149,701 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Serum”
- James Dale Berry · Brigham And Women'S Hospital$25,017,559
- Maria C Carrillo · Indiana University Indianapolis$19,445,642
- Amit Singal · Ut Southwestern Medical Center$13,798,031
- Leonard Freedman · Leidos Biomedical Research, Inc.$12,916,531
- Quy Phung · Leidos Biomedical Research, Inc.$12,889,396
- Xinhua Li · Nano Terra, Inc.$11,941,250
Research focus
SerumSpecificityResistanceScaffoldNucleic AcidsShapesProductionProstate Cancer TherapyCostMalignant NeoplasmsDesignAptamerDiagnosisDetectionLibrariesNanoparticleProstate Cancer CellInnovationBindingChemistryLncapMalignant Neoplasm Of ProstateCellsTherapeutic Agents
Grant awards (5)
Nucleic Acid Nanoparticle-based Monoclonal Antibody Mimics$560,460
R15 · FY2025 · EB · contact PI
Nucleic Acid Nanoparticle-based Monoclonal Antibody Mimics$39,695
R15 · FY2023 · EB · contact PI
Nucleic Acid Nanoparticle-based Monoclonal Antibody Mimics$417,416
R15 · FY2021 · EB · contact PI
Evaluation of Co-Delivery and Therapeutic Efficacy of siRNA and miRNA to Prostate Cancer by Nucleic Acid Nanovehicles$71,641
R03 · FY2020 · EB · contact PI
Evaluation of Co-Delivery and Therapeutic Efficacy of siRNA and miRNA to Prostate Cancer by Nucleic Acid Nanovehicles$78,060
R03 · FY2019 · EB · contact PI